Mimedx (MDXG) Research & Development (2011 - 2026)

Mimedx has disclosed Research & Development across 16 years of filings, most recently posting $4.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $4.1 million, up 24.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.9 million (up 23.99% YoY), and the FY2025 annual result was $15.1 million, up 22.33% from the prior year.
• Research & Development came in at $4.1 million for Q1 2026 at Mimedx, down from $4.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $6.0 million in Q1 2022 to a low of -$4.7 million in Q4 2022.
• The 5-year median for Research & Development is $3.5 million (2023), against an average of $3.3 million.
• Across the five-year window, Research & Development slumped 66.6% in 2022 and jumped 151.46% in 2023, its largest moves.
• Mimedx's Research & Development stood at -$4.7 million in 2022, then surged by 151.46% to $2.4 million in 2023, then soared by 46.77% to $3.6 million in 2024, then surged by 33.32% to $4.8 million in 2025, then declined by 13.04% to $4.1 million in 2026.
• The last three Research & Development figures came in at $4.1 million (Q1 2026), $4.8 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.